The treatment, developed by Orion Corporation, is in Phase 2 testing for advanced prostate cancer, and adds to Merck’s oncology pipeline

A former Celgene executive, Jackie Fouse has led Agios since 2019, overseeing its transformation into a company focused solely on uncommon diseases. In August, she will transition to chair its board of directors.

Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.

A patient in New Zealand became the first person to receive the biotech’s medicine, which uses base editing to turn off a specific gene in the liver and thereby lower cholesterol.

Flagship Pioneering’s latest startup aims to use predictive technology to find “variant-proof” treatments and vaccines for infectious diseases before they might be needed.

Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”

For $320 million, Vertex said it plans to buy ViaCyte in a deal that would provide “complementary assets, capabilities and technologies” to the ones it picked up through the 2019 acquisition of Semma Therapeutics.

Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.

The drug’s potential impact on the lung health of idiopathic pulmonary fibrosis patients, many of whom take medicines from Roche and Boehringer Ingelheim, came as a “surprise” given the study’s small size, according to one analyst.

Phase three oncology studies have approximately a 35% likelihood of leading to regulatory approval.

Clostridioides difficile infection is a highly contagious disease that affects 500,000 people in the U.S. and results in nearly 30,000 deaths per year.

In a major win for Bluebird, advisers to the agency voted 15-0 in support of its rare disease treatment eli-cel, downplaying concerns raised by FDA staff.